首页> 外文期刊>Journal of Photochemistry and Photobiology, B. Biology: Official Journal of the European Society for Photobiology >Superiority of N-methyl pyrrolidone over albumin with hypericin for fluorescence diagnosis of human bladder cancer cells implanted in the chick chorioallantoic membrane model
【24h】

Superiority of N-methyl pyrrolidone over albumin with hypericin for fluorescence diagnosis of human bladder cancer cells implanted in the chick chorioallantoic membrane model

机译:N-甲基吡咯烷酮优于白蛋白和金丝桃素的荧光诊断在鸡绒膜尿囊膜模型中植入的人膀胱癌细胞的荧光

获取原文
获取原文并翻译 | 示例
获取外文期刊封面目录资料

摘要

Formulations of hypericin (HY) with plasma protein have been conventionally used, but to date, no alternative pharmaceutical formulation has been developed for clinical use. Previously, it was reported that formulation of HY containing a biocompatible solvent and penetration enhancer, N-methyl pyrrolidone (NMP) was found to be effective for the delivery of HY across in vivo chick chorioallantoic membrane (CAM). This present study reports further investigations on the HY-NMP formulations in CAM implanted with human bladder cancer cells as a potential fluorescence diagnostic agent of cancer. The conventional formulation of HY (HY-HSA 0.5%) was included as control. The red-to-blue (I(R)/I(B)) intensity ratio of fluorescence images was used as a diagnostic algorithm, to differentiate the uptake of HY between tumor and adjacent regions on CAM. Results indicated that HY-NMP 0.05% was significantly better than HY-HSA 0.5%. The findings of the I(R)/I(B) ratios between tumor and adjacent tissues, indicated the potential of using NMP as an alternative to plasma protein in clinical fluorescence diagnosis with HY. The NMP formulations investigated were able to produce significantly higher contrast for tumor tissues and at earlier time points than was possible with HY-HSA 0.5%. (c) 2006 Elsevier B.V. All rights reserved.
机译:传统上已使用具有血浆蛋白的金丝桃素(HY)制剂,但迄今为止,尚未开发出可供临床使用的替代药物制剂。以前,据报道,含有生物相容性溶剂和渗透促进剂N-甲基吡咯烷酮(NMP)的HY制剂可有效地将HY递送至体内鸡尿囊尿膜(CAM)。本研究报告了对植入人膀胱癌细胞作为潜在的荧光诊断剂的CAM中HY-NMP制剂的进一步研究。包括常规的HY制剂(HY-HSA 0.5%)作为对照。荧光图像的红蓝(I(R)/ I(B))强度比用作诊断算法,以区分肿瘤与CAM相邻区域之间的HY摄取。结果表明,HY-NMP 0.05%明显优于HY-HSA 0.5%。肿瘤与邻近组织之间的I(R)/ I(B)比率的发现表明,在HY临床荧光诊断中,使用NMP替代血浆蛋白的潜力。与0.5%HY-HSA相比,所研究的NMP制剂能够在肿瘤组织上且在更早的时间点上产生更高的对比度。 (c)2006 Elsevier B.V.保留所有权利。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号